Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age

Next Previous
Trial Profile

A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms DETERMINATION; DFCI 10-106

Most Recent Events

  • 12 Feb 2025 According to Dana-Farber Cancer Institute media release, the study will be presented at the 2025 Tandem Meetings
  • 06 Jan 2025 Planned End Date changed from 1 Sep 2025 to 1 Dec 2026.
  • 12 Dec 2023 Results of an exploratory analysis assessing outcomes with RVd-alone vs RVd+ASCT in AA and White patients from two clinical trials: DETERMINATION and GRIFFIN presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top